MatriSys bioscience is a clinical stage dermatology microbiome company. I lead the development and the implementation of the company's strategy to advance the unique pipeline of compounds.

Affiliate Research Professor in the Center for Molecular Biology and Biotechnology (CMBB) in the Charles E. Schmidt College of science at Florida Atlantic University. Teaching clinical Research to graduate students.

Audit committee member and independent board member until December 2018.Interim CEO between December 2018 and May 2019.

Alzheimer’s disease and neurodegeneration

Economic advice to the French government.

Audit committee member.

• Successful company restart with broadening of corporate strategic direction to fully exploit breakthrough antisense oligonucleotide TGF-β technology platform • New strategic focus led to discovery of new pipeline of proprietary compounds following acquisition of LNA chemistry from Santaris (Roche)• Expanded beyond Oncology into high potential & extremely promising areas of Fibrosis & Ophthalmology • Prioritized TGF-β2 ophthalmology program with clinical PoC in glaucoma (Phase I completed in rare disease patients) and Phase II readiness in wet AMD and in glaucoma within 3 years of program initiation• Established strategic manufacturing partnership with Sanofi (Germany)• Sold trabedersen asset (1st generation) to Autotelic Inc (USA)• Raised over Euros 56m in a series of funding rounds with existing MIG Fonds investor and new Athos TG German investors • Completely restructured company: > 70% staff reduction, newly hired executive team, closed laboratories & manufacturing facilities, relocated offices to Munich, rebranded company as Isarna & set-up New York offices giving access to US investor base• Supervised complex corporate legal reorganization establishing Isarna B.V. including German & US subsidiaries• Successfully negotiated favorable settlement of major arbitration litigation in Germany

• Accelerate transfer of University of Montreal & affiliates innovations into commercial ventures• Board member Gestion Univalor & Head of Investment Committee• Developed new strategic plan to position Univalor as “1-stop-shop” for industrial partners• Initiated new operational practices to enhance revenues with staff of 25• Successfully completed a number of life-sciences & other deals• Led Quebec-wide initiative to enhance translational medicine discovery process leading to creation of the NEOMED InstituteWith this position, I expanded my field of expertise in the world of innovation to transfer discoveries to industry!Avec cette responsabilité j'ai pu élargir mon expertise au monde de l'innovation pour mieux transférer les découvertes vers l'industrie!

• Strategic & operational (sales optimization) advisory services to a range of companies• Developed strategic plans for national organizations such as the Canadian Pharmaceutical Association• Business development facilitator for local, US, EU & Japanese clients• Advised Federal academic center-of-excellence in drug discovery on commercialization strategies• Developed partnership & financing capabilities for specialized medical network

• Turnaround assignment of Quebec-based biotech also involving substantial French affiliate• Board member Ambrilia & Chairman of Ambrilia (France)• Early-stage (Phase II/III biotech) with staff of 58• Major downsizing exercise reducing staff by 75% & closing facilities in both Canada & France• Initiated “cash-preservation exercise” to reduce burn-rate & extend recent investment without dilution• Personally led tax-loss sales initiative & divestment of non-core assets• Gained new revenue sources by terminating existing distribution agreement with Covidien in the US & out of court settlement of outstanding arbitration with major Pharma company generating significant revenues• Successfully negotiated partnership agreements with ZbX (diagnostic) & Kotinos Pharma bringing in an additional $18m plus in funds• Redirected remaining funds into a new innovative “semi-virtual” biotech focused on Virology• Managed complex PR/IR activities in a “highly politicized” environment involving major job losses

• Head of Neurochem’s international development & commercialization operations• Chairman of Swiss & Luxembourg companies• Local (Canadian) operational & alliance management role• Late-stage (Phase III biotech) with staff of 256 listed on Toronto & NASDAQ stock exchanges• Reported directly to Francesco Bellini, principal investor & owner of Biochem Canada’s largest biotech• Major role in negotiating $56m partnership with Centocor for Kiacta™ (AA amyloidosis) including joint chair of the steering committee• Concluded a further 3 supply agreements for Kiacta™ & 2 for Alzhemed™• Set-up European HQ in Lausanne (staff #15) & undertook tax & IP structural optimization strategy• Supervised complex corporate reorganization transferring Headquarters to Switzerland• Participated in investor activities raising >$200m• Resolved outstanding patent litigation

• Canadian affiliate of France’s largest private pharma company with staff of 145, t/o - CAD$30m• Re-engineered sales & R&D operations in less than 1 year optimizing revenues• +23% increase revenues + increased profitability• Launched 2 major product + 3 products registered, obtained critical patent extension on Coversyl™• Key corporate defense witness in historical product liability “class-action” suit

• Multiple roles during 11 years at Roche Basel and US HQ in Nutley• Last position was Global Business Unit Head (Anti-infectives & Dermatology)• Led Rocephin® strategy and post-patent task force for US $1.3bil + brand (+11% grow)• Managed first US pharmacoeconomics program for Zenapax® a complex iv monoclonal antibody for transplantation• 3-year Sales & Marketing experience including US rep & Regional manager in Switzerland• 3-year R&D roles as International Clinical Coordinator in Basel & Nutley for12 global projects

• Local affiliate & then international Clinical Research Associate in the UK• Core team member managing leading CV drug Zestril™• Integral team member in registration & launch of pioneering antihypertensive• Contribution via Phase III trial involving protocols, investigator recruitment & data reporting• Monitored activities across affiliates & developed line-extension strategy in CHF & diabetes